Joint development of ACT101, a therapeutic antibody for SFTS
First written in FY2020. 3 of 6 entries say "Advanced", first in FY2021-Q3. Latest entry: FY2024.
No other company in this theme has enough history to compare yet.
- FY2024SoftenedAnnual report
「The company temporarily suspended the planned nonclinical studies using cynomolgus monkeys and will focus on early out-licensing using test results obtained to date. The company had also been considering veterinary in vitro diagnostic products for SFTS, for pets such as cats and dogs, but discontinued development after comprehensively considering development costs, development time and other factors.」
For ACT101, the company temporarily suspended nonclinical studies in cynomolgus monkeys and shifted its focus to early out-licensing using data already obtained. Development of veterinary in vitro diagnostic products for SFTS was also discontinued. - FY2023ReframedAnnual report
「As research and development funding will be reduced following the formation of the subsidiary, the company temporarily suspended the planned nonclinical studies using cynomolgus monkeys and will focus on early out-licensing using test results obtained to date.」
Following the reduction in research and development funding associated with AI Bio becoming a subsidiary, ACT101's nonclinical studies in cynomolgus monkeys were temporarily suspended, and the policy changed to focus on early out-licensing using data already obtained. - FY2022-Q3AdvancedAnnual report
「The company has reached the stage at which it is manufacturing master cell banks (MCBs) and working cell banks (WCBs) at a contract development and manufacturing organization (CDMO), producing the antibody, developing the manufacturing process, and conducting preclinical studies in cynomolgus monkeys.」
Development of the SFTS therapeutic antibody by AI BIO progressed through MCB and WCB manufacturing at a CDMO and antibody production and manufacturing-process development to the stage at which preclinical studies in cynomolgus monkeys could be conducted. - FY2021AdvancedAnnual report
「The company established the joint venture AI Bio Co., Ltd. with Abcontek Co. to jointly develop the antibody drug candidate ACT101 for the treatment of SFTS, a tick-borne infectious disease, and is currently constructing a production cell line suitable for manufacturing using external sources.」
Development of ACT101 progressed from the joint development agreement stage to the establishment of AI Bio and the construction of a production cell line suitable for manufacturing. - FY2021-Q3AdvancedAnnual report
「The company signed a joint development agreement with ABCONTEK Co. on 25 December 2019 concerning severe fever with thrombocytopenia syndrome (SFTS), a tick-borne infectious disease, and is advancing development of the therapeutic antibody drug candidate ACT101 with the aim of obtaining early approval. Capital: ¥20 million Date of establishment: February 2021 (scheduled) Ownership ratio: Immuno-Biological Laboratories Co.,Ltd.: 49% Abcontek Inc.: 51%」
While continuing joint development of the SFTS therapeutic antibody candidate ACT101, the parties advanced to the stage of a specific agreement premised on establishing a joint venture with ABCONTEK Co. AI Bio was scheduled to be established in February 2021, with capital of ¥20 million and ownership ratios of 49% for the company and 51% for ABCONTEK Co. - FY2020First statedAnnual report
「Agreement with Abcontek Co. for the joint development of the antibody drug candidate ACT101 to treat SFTS, a tick-borne infectious disease」
A joint development agreement was signed with Abcontek Co. on 24 December 2019, and development of the antibody candidate ACT101 for SFTS treatment began under a contract running from 1 January 2020 to 31 December 2021.